ARID1A and PPP2R1A Mutation Detection via Segmented Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective detection and diagnosis tools for identifying specific mutations in ARID1A and PPP2R1A genes, which are crucial for diagnosing and managing various types of cancer, particularly ovarian clear cell carcinoma, breast, colon, gastric, lung, medulloblastoma, and prostate cancers.
Innovation Solution
The disclosure provides methods for detecting mutations in ARID1A and PPP2R1A genes by analyzing nucleic acids and proteins, using techniques such as PCR, sequencing, and hybridization-based approaches to identify specific mutations, enabling early detection, diagnosis, and treatment monitoring of these cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used, then general cancer screening is possible, but specific mutation detection in ARID1A and PPP2R1A genes cannot be achieved
Solution Approach 1:
The patent segments the detection process into specific targeted analysis of ARID1A and PPP2R1A genes rather than general cancer screening. This segmentation allows for precise detection of mutations in these specific genes using specialized methods like next-generation sequencing and immunohistochemistry, resolving the contradiction between detection precision and method complexity by focusing resources on specific genetic targets.
Solution Approach 2:
The patent employs intermediary molecules and techniques such as oligonucleotide probes, antibodies, and sequencing intermediates that specifically bind to or detect mutations in ARID1A and PPP2R1A genes. These intermediaries enable precise mutation detection without requiring direct observation, thus achieving high measurement precision while managing device complexity through the use of specialized biological mediators.
2Reliability
If early detection methods are implemented, then patient outcomes can be improved, but current methods lack the specificity to identify ARID1A and PPP2R1A mutations
Solution Approach 1:
The patent applies preliminary action by implementing specific screening protocols and detection methods tailored for ARID1A and PPP2R1A mutations before definitive diagnosis is made. This preliminary targeted detection increases diagnosis reliability by identifying specific mutations early in the diagnostic process, making the subsequent confirmation easier and more reliable.
Solution Approach 2:
The patent replaces conventional mechanical or general biochemical detection methods with advanced molecular techniques such as next-generation sequencing and immunohistochemistry. These substituted methods specifically target ARID1A and PPP2R1A mutations, overcoming the difficulty of detection by using highly specific molecular recognition mechanisms instead of general screening approaches.
3Adaptability or versatility
If personalized treatment strategies are developed, then patient outcomes improve, but this requires accurate identification of specific gene mutations
Solution Approach 1:
The patent applies local quality by tailoring the detection approach specifically to ARID1A and PPP2R1A genes rather than using uniform detection methods across all cancer types. This localized specialized detection enables accurate mutation identification in these specific genes, which is essential for developing personalized treatment strategies that adapt to the specific genetic profile of each patient's cancer.
Solution Approach 2:
The patent utilizes parameter changes in detection sensitivity and specificity by employing advanced methods like next-generation sequencing and immunohistochemistry that can detect subtle mutations in ARID1A and PPP2R1A genes. These parameter changes in detection capability enable accurate mutation identification, which is the foundation for personalized treatment strategies that can be adapted to each patient's specific genetic profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These methods enable accurate detection and diagnosis of cancer, contributing to personalized treatment strategies and improving patient outcomes by identifying specific mutations in ARID1A and PPP2R1A genes across multiple cancer types.
Implementation Method 1
PCR, sequencing, and hybridization-based approaches
Implementation Method 2
PCR, sequencing, and hybridization-based approaches to identify specific mutations
Implementation Method 3
PCR, sequencing, and hybridization-based approaches
Data Source
AI summary
Two genes, ARID1A (AT-rich interactive domain-containing protein 1A) and PPP2R1A (protein-phosphatase 2, regulatory subunit 1, alpha), can be used in methods which are useful for detecting cancer, diagnosing cancer, contributing to a diagnosis of cancer, confirming a diagnosis of cancer, identifying appropriate treatments for cancer, monitoring treatment of cancer, and evaluating treatment protocols for cancer, including ovarian clear cell carcinoma, breast cancer, colon cancer, gastric cancer, lung cancer, medulloblastoma, pancreatic cancer, and prostate cancer.